RESUMO
Lung adenocarcinoma or non-small cell lung cancer (NSCLC) represents one of the most diagnosed cancers worldwide. Anaplastic lymphoma kinase (ALK) mutation, a tyrosine kinase and ALK fusion or rearrangement oncogene, has been found rarely in patients with NSCLC. Newer treatment modalities with different ALK inhibitors in targetable specific ALK mutations have recently made great strides in the management of NSCLC patients. We present a case of NSCLC harboring ALK mutation with primary cutaneous marginal zone B-cell lymphoma (PCMZL) treated with adjuvant chemotherapy with pemetrexed and cisplatin, and ALK-echinoderm microtubule-associated protein-like 4 (EML4)-targeting treatment alectinib.
RESUMO
BACKGROUND: Each year, approximately 8000 cases of cholangiocarcinoma are recorded in the USA. Surgical resection is considered to be the only curative option. Despite surgery as a curative approach, many patients will require adjuvant therapies in the form of chemotherapy (ChT) or chemoradiotherapy (CRT). As such, we sought to analyze outcomes in patients with non-metastatic cholangiocarcinoma receiving adjuvant ChT or CRT following surgical resection. METHODS: We queried the National Cancer Database (NCDB) for patients with a diagnosis of non-metastatic cholangiocarcinoma between the years 2010 and 2015 who underwent adjuvant ChT or CRT following surgery. Overall survival (OS) was calculated using Kaplan Meier method. Cox proportional hazard ratios were used to identify predictors of overall survival, and logistic regression was used to identify predictors of receiving each treatment. RESULTS: A total of 875 patients were identified who met the above eligibility criteria. Of these patients, 818 received adjuvant chemotherapy alone with 57 patients receiving adjuvant chemoradiation therapy. The median OS in patients receiving CRT was 19.8 months versus 11.9 months for ChT (p value < 0.0238). The 1- and 5-year survival rates between ChT and CRT were 50% vs 61% and 6% vs 13%, respectively (hazard ratio 0.7005; 95% CI 0.51-0.97; p value < 0.0294). CONCLUSION: The results of this study suggest a potential benefit of chemoradiation therapy in the adjuvant setting, although the trends appear to show rare utilization. Given the limitations of our study, prospective corroboration is warranted.
Assuntos
Neoplasias dos Ductos Biliares , Colangiocarcinoma , Neoplasias dos Ductos Biliares/patologia , Ductos Biliares Intra-Hepáticos/patologia , Quimiorradioterapia Adjuvante/métodos , Quimioterapia Adjuvante , Colangiocarcinoma/patologia , Humanos , Estadiamento de NeoplasiasRESUMO
Purpose This study was conducted to determine factors that influence palliative care (PC) consultation in patients receiving cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). Patient and methods We queried our Electronic Medical Record EPIC for a list of patients who underwent cytoreductive surgery with HIPEC or hyperthermic intrathoracic chemotherapy (HITEC) in the hospital from April 2016-April 2019. Data was manually extracted and patients who did not meet our criteria were excluded. Patients were divided on the basis of palliative care consults and differences between the groups were analyzed. Odds ratios (OR) with p-value of 0.05 and confidence interval of (CI) 95% were calculated. Results We identified 55 patients of whom 34 met our inclusion criteria: 11 males and 23 females with an average age of 56 years at the time of diagnosis. Eight patients (23%) had PC, with six having commercial insurance, seven married, and six with more than one comorbid medical issue. Comorbidities >1 (OR: 0.12; CI: 0.02-0.76; p: 0.02) and age >40 (OR: 0.015; CI: 0.0007-0.3029; P: 0.006) were associated with a higher likelihood of PC. Gender, insurance type, and marital status did not have a significant association with PC. Mean age between PC consulted patients versus non-PC consulted patients was 58.5 vs. 55.9 and median age between the two groups was 60.5 vs. 60 which also showed a trend towards higher rates of PC in the older population. Conclusion Approximately one quarter of patients who underwent CRS with HIPEC had a concurrent PC consult. Though this is better than the national average of 11-16%, it continues to be a very small number. Efforts must be made to engage PC early in the course of treatment and recognize it as an integral part of cancer care. PC is not only an end-of-life service, in fact, studies have shown that early consultations lead to higher patient satisfaction, improved quality of life, and better communication.
RESUMO
Chronic lymphocytic leukemia is the most common blood cancer in adults. A major cause of morbidity and mortality associated with this cancer stems from opportunistic infections. Similar to many cancers, the inherent effects of battling a raging disease along with the many treatment options causing immunosuppression to lend to the likelihood of obtaining secondary infections. As it is important for physicians to note the ever-increasing secondary complications, which can manifest in the long-term management of immunosuppressed patients, we present a case of an 86-year-old Caucasian female with stable chronic lymphocytic leukemia who developed intermittent presentation of lung abscesses due to growth of atypical Mycobacterium species. With the advent of new treatment options, there has been an increased rate of drug-resistant organisms, lending for the need for more awareness to the severity of these secondary complications and for better options in preventing their occurrence.
RESUMO
In vitro gastrointestinal (IVG) methods have been developed to provide an expedient and inexpensive means to estimate bioavailability of arsenic and other contaminants from ingestion of contaminated soil. Both in vivo and in vitro techniques have used a fasting model when determining Pb bioavailability/bioaccessibility as a conservative estimate of risk. Some IVG procedures have incorporated a dosing vehicle (DV) or food (i.e., milk) to simulate in vivo conditions. Potential differences in the bioaccessibility of contaminants between fasting and fed states remain a concern for those interested in adopting in vitro procedures for regulatory purposes. In this study, the effect of eliminating a dough-like DV on As bioaccessibility (BA), and this effect on the relationship between in vitro bioaccessible and in vivo relative bioavailability (RBA) As is determined. Also, the effect of phosphate from the DV on IVG BA is investigated. Two types of smelter-contaminated soils, calcine and iron slag, were used to examine the effect of dosing vehicle (DV) on BA determined by IVG. Dosing vehicle did not affect BA in the gastric extraction (GE) or intestinal extraction (IE) for 3 of the 5 calcinated contaminated soils. Inclusion of DV in the GE slightly increased BA for 2 of the 5 slag-contaminated soils. Increases in BA from DV may be attributed to ligand exchange of arsenate with phosphate. Strong relationships between BA and in vivo RBA As were found with or without DV. Bioaccessible As measured by the GE was strongly correlated with in vivo RBA As (IVG without DV: r=0.92, P<0.01; IVG with DV: r=0.96; P<0.01). Similarly, BA measured by the IE was strongly correlated with in vivo RBA As (IVG without DV: r=0.90, P<0.01; IVG with DV: r=0.96, P<0.01). The IVG method, with or without DV, is a reliable method to use as a rapid screening tool to provide an estimate of BA in contaminated soils. Further studies should be conducted to determine the influence of foodstuffs on BA for different types of As contaminated soil (i.e., non-smelter soil).